On the way to recoveryThe Vidi programme targets excellent researchers with several years of experience after their PhD. These researchers belong to the best of their respective disciplines. The Vidi programme enables them to do research for five years, which is how NWO hopes to stimulate innovation in science.
Vidi grant for Vivian Weerdesteyn - Theme Disorders of movement
Following a stroke, humans often struggle with balance and walking. This impacts their safety and autonomy tremendously, which is a problem especially in our aging society. It is still unknown how different neural pathways contribute to the recovery of balance and walking after a stroke. Dr. Weerdesteyn and her colleagues are going to change this. They will furthermore attempt to facilitate recovery through training in order to improve functioning in daily life.
> see the personal page of Vivian Weerdesteyn for more information about her research
Vivian Weerdesteyn PhD
Related news items
Lowering cholesterol is not enough to reduce hyperactivity of the immune system14 June 2019
In Cell Metabolism, Siroon Bekkering, theme Vascular damage, and colleagues, provides a novel potential explanation for the residual cardiovascular risk, related to persistent activation of the immune system in patients with hypercholesterolemia who are treated with statins.read more
A personal touch of Johan van der Vlag13 June 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Johan van der Vlag.read more
Peter van der Kraan new theme leader Inflammatory diseases13 June 2019
It is our pleasure to introduce Peter van der Kraan from the Dept. of Rheumatology, as the new leader of our theme Inflammatory diseases. As such he will be the successor of Irma Joosten who has done an outstanding job in the last years as theme leader, for which we thank her wholeheartedly.read more
Intake of a reduced dose of pazopanib with food the effect on pharmacokinetics, patient safety and preference13 June 2019
In Clinical Pharmacology & Therapeutics Floor Lubberman and colleagues showed that the intake of 600mg pazopanib with food resulted in a bioequivalent exposure and was preferred over a standard pazopanib dose without food.read more